LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRXBiotechnology
-$0.39 today
- Market cap
- $1.30B
- Beta
- 0.71
- P/E (TTM)
- -21.4
- EPS (TTM)
- -$1.39
Volume 0.36M
Average 0.23M
LBRX Other Current Assets
Current assets not reported separately, such as prepaid expenses.
LB Pharmaceuticals Inc Common StockNASDAQ: LBRX
Other Current Assets · Q1 FY2026 · quarter ended Mar 2026
Other current assets remains negative
Q1 FY2026 other current assets was $20.8M, compared with $0 a year earlier. Over 3 fiscal years it compounded at +976.7% a year.
Context
- Other current assets amounted to 5.3% of total assets at the end of Q1 FY2026, up 5.3 pp from a year earlier.
- Other current assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 11.24M USD
- Year-over-year change
- +8411.4%
- 3-year CAGR
- +976.7%
| Period | Period end | Other Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.24M | +8411.4% |
| FY2024 | 2024-12-31 | 132K | +407.7% |
| FY2023 | 2023-12-31 | 26K | +188.9% |
| FY2022 | 2022-12-31 | 9K | — |
Other Current Assets vs competitors
How LBRX compares with its peers on the latest reported figures
- LBRX's Mar 2026 other current assets of $20.8M is the 3rd highest of the 10 companies compared; the peer median is $6.36M.
- Other current assets amounts to 5.3% of total assets for LBRX, versus a peer median of 1.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $4.47B | +1490234.9% | -41.9% | 4.7% | |
| Sep 2026 | $90.6M | — | — | 5.0% | |
LBRXLB Pharmaceuticals Inc Common Stock | Mar 2026 | $20.8M | — | +976.7% | 5.3% |
| Mar 2026 | $17.12M | — | +64.9% | 4.1% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $7.86M | +40.6% | — | 1.6% |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $6.36M | +15.4% | +443.0% | 4.1% |
| Mar 2026 | $5.36M | +23221.7% | — | 1.9% | |
| Mar 2026 | $4.91M | +47.8% | — | 1.8% | |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | $0 | -100.0% | — | 0.0% |
| Jun 2026 | $0 | -100.0% | — | 0.0% | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding LBRX) | $6.36M | +40.6% | +64.9% | 1.9% | |
Competitors are the stored peer set for LBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
Intrinsic Alpha fair value
Locked
Current Price
$40.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.